Aurinia Pharmaceuticals (AUPH) Cash from Investing Activities (2020 - 2026)

Aurinia Pharmaceuticals has reported Cash from Investing Activities for 7 years, with the latest figure at -$18.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 158.26% year-over-year to -$18.1 million; the trailing twelve-month figure through Mar 2026 stood at -$81.9 million (down 488.78% YoY), and the FY2025 full-year result was -$32.8 million, down 183.46% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$18.1 million, up from -$36.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $49.2 million in Q1 2024, with the low at -$53.0 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$4.6 million across 5 years, with a median of -$10.6 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 2631.8% — and 2024, when it slumped 588.69%.
• Aurinia Pharmaceuticals' Cash from Investing Activities stood at -$3.0 million in 2022, then plunged by 107.32% to -$6.3 million in 2023, then soared by 726.87% to $39.2 million in 2024, then plunged by 193.71% to -$36.8 million in 2025, then soared by 50.81% to -$18.1 million in 2026.
• The last three Cash from Investing Activities figures came in at -$18.1 million (Q1 2026), -$36.8 million (Q4 2025), and -$13.8 million (Q3 2025), per Business Quant data.